日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development

肝脏分子失调导致非病毒相关肝细胞癌发生的多组学分析

Nakahara, Hikaru; Ono, Atsushi; Hayes, C Nelson; Shirane, Yuki; Miura, Ryoichi; Fujii, Yasutoshi; Tamura, Yosuke; Uchikawa, Shinsuke; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Yamauchi, Masami; Kawaoka, Tomokazu; Miki, Daiki; Tsuge, Masataka; Kobayashi, Tsuyoshi; Ohdan, Hideki; Arihiro, Koji; Oka, Shiro

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma

阿特珠单抗联合贝伐珠单抗治疗伴有门静脉高压的不可切除肝细胞癌患者的疗效和安全性

Kinami, Takahiro; Uchikawa, Shinsuke; Kawaoka, Tomokazu; Yamasaki, Shintaro; Kosaka, Masanari; Johira, Yusuke; Yano, Shigeki; Amioka, Kei; Naruto, Kensuke; Yamaoka, Kenji; Fujii, Yasutoshi; Fujino, Hatsue; Nakahara, Takashi; Ono, Atsushi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Miki, Daiki; Tsuge, Masataka; Oka, Shiro

Correction: Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography

更正:应用对比增强超声评估阿特珠单抗联合贝伐珠单抗治疗肝细胞癌的效果

Uchikawa, Shinsuke; Kawaoka, Tomokazu; Fujino, Hatsue; Ono, Atsushi; Nakahara, Takashi; Murakami, Eisuke; Yamauchi, Masami; Miki, Daiki; Imamura, Michio; Aikata, Hiroshi

Successful outcome achieved with adjuvant chemotherapy with irinotecan plus cisplatin in rectal neuroendocrine carcinoma: a case report

伊立替康联合顺铂辅助化疗治疗直肠神经内分泌癌取得成功:病例报告

Saegusa, Yoshitaka; Akabane, Shintaro; Shimomura, Manabu; Okuda, Hiroshi; Yano, Takuya; Mochizuki, Tetsuya; Inoue, Wako; Yamaguchi, Mizuki; Yamaguchi, Shinji; Sentani, Kazuhiro; Yamauchi, Masami; Tokumo, Kentaro; Ohdan, Hideki

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment

钆塞酸增强磁共振成像肝胆期与免疫微环境及阿特珠单抗联合贝伐珠单抗治疗反应的相关性

Tamura, Yosuke; Ono, Atsushi; Nakahara, Hikaru; Hayes, Clair Nelson; Fujii, Yasutoshi; Zhang, Peiyi; Yamauchi, Masami; Uchikawa, Shinsuke; Teraoka, Yuji; Uchida, Takuro; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Tsuge, Masataka; Serikawa, Masahiro; Miki, Daiki; Kawaoka, Tomokazu; Okamoto, Wataru; Imamura, Michio; Nakamura, Yuko; Awai, Kazuo; Kobayashi, Tsuyoshi; Ohdan, Hideki; Fujita, Masashi; Nakagawa, Hidewaki; Chayama, Kazuaki; Aikata, Hiroshi; Oka, Shiro

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

过渡到新的MAFLD分类对非B、非C型肝细胞癌的影响和实用性:一项回顾性队列研究

Johira, Yusuke; Nakahara, Takashi; Kinami, Takahiro; Yamasaki, Shintaro; Kosaka, Masanari; Shirane, Yuki; Miura, Ryoichi; Murakami, Serami; Yano, Shigeki; Amioka, Kei; Naruto, Kensuke; Ando, Yuwa; Kosaka, Yumi; Kodama, Kenichiro; Uchikawa, Shinsuke; Fujino, Hatsue; Ono, Atsushi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Kawaoka, Tomokazu; Hayes, C Nelson; Tsuge, Masataka; Imamura, Michio; Aikata, Hiroshi; Oka, Shiro

Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer

STK11 和 KEAP1 基因的共突变导致 KRAS 野生型非小细胞肺癌产生治疗耐药性

Sumii, Masahiko; Namba, Masashi; Tokumo, Kentaro; Yamauchi, Masami; Okamoto, Wataru; Hattori, Noboru; Sugiyama, Kazuhiko

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

乐伐替尼通过抑制晚期肝细胞癌肿瘤微环境中的免疫抑制细胞浸润来激活抗肿瘤免疫。

Yamauchi, Masami; Ono, Atsushi; Amioka, Kei; Fujii, Yasutoshi; Nakahara, Hikaru; Teraoka, Yuji; Uchikawa, Shinsuke; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Miki, Daiki; Kawaoka, Tomokazu; Tsuge, Masataka; Imamura, Michio; Hayes, C Nelson; Ohishi, Waka; Kishi, Takeshi; Kimura, Mizuki; Suzuki, Natsumi; Arihiro, Koji; Aikata, Hiroshi; Chayama, Kazuaki; Oka, Shiro

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者对乐伐替尼的生存率和疗效分析

Amioka, Kei; Kawaoka, Tomokazu; Kosaka, Masanari; Johira, Yusuke; Shirane, Yuki; Miura, Ryoichi; Murakami, Serami; Yano, Shigeki; Naruto, Kensuke; Ando, Yuwa; Kosaka, Yumi; Fujii, Yasutoshi; Kodama, Kenichiro; Uchikawa, Shinsuke; Fujino, Hatsue; Ono, Atsushi; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Imamura, Michio; Mori, Nami; Takaki, Shintaro; Tsuji, Keiji; Masaki, Keiichi; Honda, Yoji; Kouno, Hirotaka; Kohno, Hiroshi; Moriya, Takashi; Naeshiro, Noriaki; Nonaka, Michihiro; Hyogo, Hideyuki; Aisaka, Yasuyuki; Azakami, Takahiro; Hiramatsu, Akira; Aikata, Hiroshi

Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

日本各类实体瘤患者接受免疫检查点抑制剂治疗后免疫相关不良事件的发生率及抗肿瘤疗效

Yoshikawa, Yuki; Imamura, Michio; Yamauchi, Masami; Hayes, C Nelson; Aikata, Hiroshi; Okamoto, Wataru; Miyata, Yoshihiro; Okada, Morihito; Hattori, Noboru; Sugiyama, Kazuhiko; Yoshioka, Yukio; Toratani, Shigeaki; Takechi, Masaaki; Ichinohe, Tatsuo; Ueda, Tsutomu; Takeno, Sachio; Kobayashi, Tsuyoshi; Ohdan, Hideki; Teishima, Jun; Hide, Michihiro; Nagata, Yasushi; Kudo, Yoshiki; Iida, Koji; Chayama, Kazuaki